←Back to Expert Scholars
Translational Medicine / 转化医学AML Novel Targets, IDH and Novel Agents
Amir Fathi
MD
🏢Massachusetts General Hospital Cancer Center🌐USA
Director, Leukemia Program
55
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Amir Fathi directs the leukemia program at MGH and has contributed to trials of olutasidenib, enasidenib, and ivosidenib establishing IDH-directed therapy. He has led studies of novel agents and combinations in AML and MDS. His work has expanded targeted therapy options for AML.
Share:
🧪Research Fields 研究领域
IDH1/2 inhibitors
olutasidenib
AML novel targets
venetoclax combinations
MDS/AML trials
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Amir Fathi 的研究动态
Follow Amir Fathi's research updates
留下邮箱，当我们发布与 Amir Fathi（Massachusetts General Hospital Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment